119 HR 4605 IH: End Prescription Drug Ads Now Act U.S. House of Representatives 2025-07-22 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I119th CONGRESS1st SessionH. R. 4605IN THE HOUSE OF REPRESENTATIVESJuly 22, 2025Mr. Nadler (for himself and Ms. Dexter) introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo ban drug manufacturers from using direct-to-consumer advertising, including social media, to promote their products.

1.

Short title

This Act may be cited as the End Prescription Drug Ads Now Act.

2.

Prohibition on direct-to-consumer drug advertising of drugs

(a)

In general

Section 502 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the following: (hh) (1)If it is a drug approved under section 505 or licensed under section 351 of the Public Health Service Act, and subject to section 503(b)(1), and the holder of the approved application under section 505 or of the license under such section 351 has conducted direct-to-consumer advertising of the drug within the most recent 30-day period. (2)For purposes of this paragraph, the term direct-to-consumer advertising, with respect to a drug subject to section 503(b)(1), means any promotional communication targeting consumers, including through television, radio, print media, digital platforms, and social media, for purposes of marketing such a drug.. (b)

Effective date

The amendment made by subsection (a) shall take effect 30 days after the date of enactment of this Act, and shall apply with respect to any drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or licensed under section 351 of the Public Health Service Act (42 U.S.C. 262), regardless of when the drug was approved or licensed.